Epizyme, Inc. (NASDAQ:EPZM) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

EPZM has been the topic of a number of other research reports. BidaskClub lowered Epizyme from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 target price on the stock. Cann reaffirmed a “buy” rating and issued a $26.00 target price on shares of Epizyme in a report on Thursday. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. Epizyme has an average rating of “Buy” and an average price target of $22.67.

Epizyme (NASDAQ:EPZM) traded up $0.05 on Monday, reaching $14.25. The company’s stock had a trading volume of 438,129 shares, compared to its average volume of 587,390. Epizyme has a 12-month low of $8.90 and a 12-month high of $20.45.

Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. equities research analysts forecast that Epizyme will post -2.25 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Epizyme, Inc. (EPZM) Downgraded by ValuEngine” was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/epizyme-inc-epzm-downgraded-by-valuengine/1683988.html.

In other news, Director David M. Mott acquired 200,000 shares of Epizyme stock in a transaction on Monday, September 18th. The stock was bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the transaction, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at approximately $348,535.04. The disclosure for this sale can be found here. Insiders sold a total of 45,000 shares of company stock valued at $733,950 in the last quarter. Corporate insiders own 25.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc lifted its position in shares of Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new position in shares of Epizyme during the 1st quarter worth approximately $175,000. BB&T Securities LLC bought a new position in shares of Epizyme during the 2nd quarter worth approximately $181,000. Trexquant Investment LP bought a new position in shares of Epizyme during the 2nd quarter worth approximately $184,000. Finally, SG Americas Securities LLC lifted its position in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the period. Institutional investors and hedge funds own 72.20% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.